Nurix Therapeutics (NRIX) News Today → Thousands of investors use this no cost solution | Do you? (From Insider Financial) (Ad) Free NRIX Stock Alerts $12.36 -1.39 (-10.11%) (As of 04/25/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineNurix Therapeutics (NASDAQ:NRIX) Shares Gap Up to $14.65americanbankingnews.com - April 19 at 5:36 AMNurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Sharesstockhouse.com - April 18 at 4:24 PMNurix Therapeutics (NRIX) Price Target Increased by 5.58% to 25.09msn.com - April 17 at 10:44 PMNurix Therapeutics (NASDAQ:NRIX) Shares Down 4.7% marketbeat.com - April 16 at 1:41 PMNurix Therapeutics (NASDAQ:NRIX) Climbs Higher After Beating Expectationsmsn.com - April 15 at 12:52 PMNurix Therapeutics Advances Promising Protein Degraders For B-Cell Malignanciesseekingalpha.com - April 15 at 7:30 AMShares of Nurix Therapeutics Down 6% on Plans for Stock Salemarketwatch.com - April 12 at 8:09 PMNurix Therapeutics prices upsized stock offering to raise $175 millionseekingalpha.com - April 12 at 10:07 AMNurix Therapeutics Announces $125 Mln Public Stock Offering; Stock Down In After-hoursmarkets.businessinsider.com - April 11 at 11:56 PMNurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offeringglobenewswire.com - April 11 at 11:38 PMNurix Therapeutics Announces Proposed Public Offeringglobenewswire.com - April 11 at 4:00 PMRoyal Bank of Canada Raises Nurix Therapeutics (NASDAQ:NRIX) Price Target to $23.00marketbeat.com - April 11 at 11:01 AMNurix Therapeutics (NASDAQ:NRIX) Shares Gap Up on Analyst Upgrademarketbeat.com - April 11 at 10:24 AMNurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Consensus Rating of "Moderate Buy" from Analystsmarketbeat.com - April 11 at 8:18 AMNurix Therapeutics (NASDAQ:NRIX) Trading Down 7.2%marketbeat.com - April 10 at 3:46 PMNurix Therapeutics, Inc.: Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Updatefinanznachrichten.de - April 10 at 12:16 PMNurix Therapeutics, Inc. Q1 Loss increases, but beats estimatesmarkets.businessinsider.com - April 10 at 12:16 PMNurix Therapeutics Inc (NRIX) Misses Earnings Predictions But Shows Revenue Growth in Q1 Fiscal 2024finance.yahoo.com - April 10 at 12:16 PMNRIX Stock Earnings: Nurix Therapeutics Beats EPS, Misses Revenue for Q1 2024msn.com - April 10 at 12:16 PMNurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Updateglobenewswire.com - April 10 at 7:00 AMNurix Therapeutics Shares Climb 19% on Extended Sanofi Collaborationmarketwatch.com - April 9 at 4:14 PMNurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignanciesglobenewswire.com - April 9 at 1:15 PMNurix Therapeutics (NASDAQ:NRIX) Trading 3.9% Higher marketbeat.com - April 9 at 11:46 AMNurix Therapeutics (NASDAQ:NRIX) Given "Buy" Rating at Needham & Company LLCmarketbeat.com - April 9 at 8:30 AMNurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6globenewswire.com - April 9 at 7:00 AMNurix Therapeutics (NASDAQ:NRIX) Shares Down 4% marketbeat.com - April 3 at 3:26 PMNurix Therapeutics to Participate in Upcoming Investor Conferencesglobenewswire.com - April 3 at 7:00 AMNurix Therapeutics Earns ‘Buy’ Rating on Strong Partnerships and Revenue Potentialmarkets.businessinsider.com - April 2 at 1:57 PMCritical Insights From Nurix Therapeutics Analyst Ratings: What You Need To Knowmarkets.businessinsider.com - April 2 at 1:57 PMNurix Therapeutics (NASDAQ:NRIX) Receives Buy Rating from Needham & Company LLCmarketbeat.com - April 2 at 10:09 AMNurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciencesfinance.yahoo.com - April 2 at 8:57 AMNurix Therapeutics Says Gilead Sciences Extends Ongoing Strategic Collaboration By Addl. Two Yearsmarkets.businessinsider.com - April 2 at 8:57 AMNurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciencesglobenewswire.com - April 2 at 7:00 AMARK Investment Management LLC Acquires 601,952 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)marketbeat.com - March 28 at 6:39 AMNurix Therapeutics (NASDAQ:NRIX) Shares Up 8.3%marketbeat.com - March 27 at 5:23 PMNurix Therapeutics (NASDAQ:NRIX) Shares Down 3.6% marketbeat.com - March 26 at 4:22 PMNurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD)globenewswire.com - March 25 at 7:00 AMNurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) Meetingglobenewswire.com - March 20 at 9:40 AMNRIX Oct 2024 20.000 callfinance.yahoo.com - March 12 at 6:58 PMNurix Therapeutics Gains Analyst Confidence with Advancements in Clinical Programs and Strategic Focus on NHLmarkets.businessinsider.com - March 12 at 1:58 PMBuy Rating Reaffirmed for Nurix Therapeutics Following FDA’s Lift of Clinical Hold on Cancer Drug NX-2127markets.businessinsider.com - March 12 at 8:58 AMAnalyst Scoreboard: 7 Ratings For Nurix Therapeuticsmarkets.businessinsider.com - March 11 at 3:23 PMNurix Therapeutics: FDA Lifts Partial Clinical Hold on NX-2127 Studymarketwatch.com - March 11 at 8:36 AMNurix Therapeutics: FDA Lifts Partial Clinical Hold On NX-2127 Phase 1 Trialmarkets.businessinsider.com - March 11 at 8:36 AMNurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trialfinance.yahoo.com - March 11 at 8:36 AMKennedy Capital Management LLC Purchases 107,719 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)marketbeat.com - March 11 at 6:53 AMGSA Capital Partners LLP Acquires 177,852 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)marketbeat.com - March 8 at 8:37 AMNurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2024 Annual Meetingmarkets.businessinsider.com - March 6 at 4:44 PMNurix Therapeutics to Participate in Upcoming Investor Conferencesfinance.yahoo.com - March 6 at 4:44 PMNurix Therapeutics to Participate in Upcoming Investor Conferencesglobenewswire.com - March 6 at 4:00 PM Get Nurix Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NRIX and its competitors with MarketBeat's FREE daily newsletter. Email Address Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (Ad)Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow. Click here for your free guide NRIX Media Mentions By Week NRIX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NRIX News Sentiment▼0.530.41▲Average Medical News Sentiment NRIX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NRIX Articles This Week▼13▲NRIX Articles Average Week Get Nurix Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NRIX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: DNTH News PRTC News BCYC News EOLS News SLN News YMAB News COGT News LBPH News AUPH News IRON News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NRIX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsThe AI stock to buy right nowStockEarningsThe only accurate crypto trading system I know …Weiss RatingsFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nurix Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
